Pehal Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 4.17 Cr
as on 08-01-2025
- Paid Up Capital ₹ 1.74 M
as on 08-01-2025
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.93 Cr
as on 08-01-2025
- Revenue 435.35%
(FY 2022)
- Profit -1015.82%
(FY 2022)
- Ebitda -1413.37%
(FY 2022)
- Net Worth -152.88%
(FY 2022)
- Total Assets 84.59%
(FY 2022)
About Pehal Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.17 Cr and a paid-up capital of Rs 1.74 M.
The company currently has active open charges totaling ₹1.93 Cr.
Rekha Sanjay and Sanjay Madanraj serve as directors at the Company.
- CIN/LLPIN
U74999MH2016PTC282589
- Company No.
282589
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jun 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pehal Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Madanraj  | Managing Director | 20-Jun-2016 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rekha Sanjay | Director | 20-Jun-2016 | Current |
Financial Performance of Pehal Life Sciences.
Pehal Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 435.35% increase. The company also saw a substantial fall in profitability, with a 1015.82% decrease in profit. The company's net worth observed a substantial decline by a decrease of 152.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pehal Life Sciences?
In 2022, Pehal Life Sciences had a promoter holding of 78.79% and a public holding of 21.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pehal Manufacturing & General Trading LimitedActive 21 years 3 monthsSanjay Madanraj is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Jun 2022 | ₹1.93 Cr | Open |
How Many Employees Work at Pehal Life Sciences?
Pehal Life Sciences has a workforce of 13 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pehal Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pehal Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
